A phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and phase I study of this drug for recurrent or refractory neuroblastoma
Phase of Trial: Phase I/II
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Crizotinib (Primary)
- Indications Anaplastic large cell lymphoma; Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 19 Nov 2018 Status changed from recruiting to suspended.
- 18 Oct 2017 Status changed from not yet recruiting to recruiting.
- 21 Jul 2017 New trial record